Form 8-K ADMA BIOLOGICS, INC. For: Feb 08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 8, 2023
|
(Exact name of registrant as specified in its charter)
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (201 )
478-5552
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
Item 8.01 |
Other Events
|
On February 8, 2023, ADMA Biologics, Inc. issued a press release announcing that it has received U.S. Food and Drug Administration (“FDA”) approval for
its eighth ADMA BioCenters plasma collection facility located in Hammond, Louisiana (the “Facility”). This plasma collection facility commenced operations and initiated source plasma collection in the second quarter of 2022. With the approval, the
Facility is now FDA-approved to collect and introduce into interstate commerce, human source plasma for further manufacturing in the United States. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.
Item 9.01 |
Exhibits.
|
(d) |
Exhibits
|
Exhibit No.
|
Description
|
ADMA Biologics, Inc. Press Release, dated February 8, 2023
|
|
104
|
Cover Page Interactive Data File (embedded with the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
February 8, 2023
|
ADMA Biologics, Inc.
|
||
By:
|
/s/ Brian Lenz
|
||
Name:
|
Brian Lenz
|
||
Title:
|
Executive Vice President and Chief Financial Officer
|
ATTACHMENTS / EXHIBITS
XBRL TAXONOMY EXTENSION SCHEMA
XBRL TAXONOMY EXTENSION LABEL LINKBASE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Media Advisory: Day of Mourning 2024 - CLC Executive Vice-President Siobhán Vipond to attend Ottawa-area events
- Tufts Medicine, Navvis Partner to Accelerate Value-Based Care, Driving Healthcare Transformation in Massachusetts
- Genco Shipping & Trading Limited Mails Letter to Shareholders
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!